Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEarly termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
BMC Cancer, 10/22/09
Robe PA et al. – Although the proper influence of sulfasalazine treatment on patient outcome was difficult to ascertain in these debilitated patients with a large tumor burden (median KPS=50), ISRCTN45828668 was terminated after its interim analysis. This study urges to exert cautiousness in future trials of Sulfasalazine for the treatment of malignant gliomas
Methods- 10 patients with advanced recurrent anaplastic astrocytoma (n=2) or glioblastoma (n=8) aged 32-62 years recruited prior to planned interim analysis of study
- Subjects randomly assigned to daily doses of 1.5, 3, 4.5, or 6 grams of oral sulfasalazine, and treated until clinical or radiological evidence of disease progression or development of serious or unbearable side effects
- Primary endpoints were evaluation of toxicities according to CTCAE v.3.0, and observation of radiological tumor responses based on MacDonald criteria
- No clinical response observed
- One tumor remained stable for 2 months with sulfasalazine treatment, at the lowest daily dose of drug
- Median progression-free survival was 32 days
- Side effects common, as all patients developed grade 1-3 adverse events (mean: 7.2/patient), four patients developed grade 4 toxicity
- 2 patients died while on treatment or shortly after discontinuation
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiosurgery and whole brain therapy in the treatment of brainstem metastases
Clinical and Translational Oncology, 11/25/09
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2
Virchows Archiv, 11/25/09
Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines
Pediatric Hematology and Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor